Comparing closed-loop insulin therapy and islet transplantation for unstable type 1 diabetes
Observes adults with unstable type 1 diabetes to compare closed-loop insulin therapy with islet transplantation.
Plain-language title generated from the registry record
Registry title: Cohort Study to Refine the Positioning of Closed-loop Therapy Versus Islet Transplantation in the Management of Patients With Unstable Type 1 Diabetes
Key facts
- Where
- La Tronche, Lyon, Montpellier, Paris, Pierre-Bénite, Strasbourg, and Toulouse, FranceSee the 7 sites
Where in France
- Grenoble University HospitalLa Tronche, FranceTaking people
- HCL - Edouard Herriot HospitalLyon, FranceTaking people
- Montpellier University Hospital - Lapeyronnie HospitalMontpellier, FranceTaking people
- APH Paris - LARIBOISIERE HospitalParis, FranceNot yet recruiting
- Hospices Civils de Lyon -Lyon SudPierre-Bénite, FranceTaking people
- Strasbourg Civil HospitalStrasbourg, FranceTaking people
- Toulouse University Hospital - Hôpital RangueilToulouse, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Grenoble
- Trial code
- NCT07006272
- Record updated
- 28 July 2025
- Original description
Prospective, multicenter, descriptive cohort (RIPH3 study under the Jardé Act), STABILOOP study aims to describe whether BF may be an appropriate therapeutic option for the cohort of patients who are theoretically candidates for Islet transplantation, by describing Closed-Loop failures at 12 months in patients referred to an expert center for management of unstable diabetes.Read full original descriptionShow less
Cohort Study to Refine the Positioning of Closed-loop Therapy Versus Islet Transplantation in the Management of Patients With Unstable Type 1 Diabetes
Prospective, multicenter, descriptive cohort (RIPH3 study under the Jardé Act), STABILOOP study aims to describe whether BF may be an appropriate therapeutic option for the cohort of patients who are theoretically candidates for Islet transplantation, by describing Closed-Loop failures at 12 months in patients referred to an expert center for management of unstable diabetes.
Inclusion: Type 1 diabetic patients describing:; Significant glycaemic variability defined by the presence of one of these 3 criteria: - Standard deviation > 50% of the glycaemic mean or a MAGE index > 60 mg/dL; Coefficient of glycaemic variation > 36%; LBGI index > 5 or HYPOSCORE > 800; This glycaemic variability must be persistent, i.e. persist for more than 12 months despite optimal diabetes management by a multi-professional team. Optimum management involves :; Monitoring by a team with expertise in insulin pump and glucose sensor technologies; Training patients in functional insulin therapy, intensive self-monitoring of blood glucose levels, and prevention and management of situations where there is a risk of hypoglycaemia; Use of pump and glucose sensor therapy, with interruption before hypoglycaemia; Reinforced multi-professional support and monitoring, possibly combined with support via telemedicine; This glycaemic variability must be considered as severe, i.e. causing unpredictable clinical and metabolic events that impair quality of life, such as severe, disabling and frequent hypoglycaemia (at least 2 Severe Hypoglycaemia with assistance from a third party in the last 12 months or at least 1 Severe Hypoglycaemia with life-threatening consequences in the last 12 months (coma, convulsions or trauma)) or ketosis ketoacidosis.
Exclusion: Kidney transplant patients; Patients with type 1 diabetes who do not meet the criteria for islet transplantation; Patients already fitted with a closed loop; Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons); Persons opposed to participation in research.